VALEO PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 CAD | -.--% |
|
+1.54% | -10.81% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
| Sales 2024 * | 61M 44.68M | Sales 2025 * | 75.83M 55.54M | Capitalization | 9.37M 6.87M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -13.18M | Net income 2025 * | -12M -8.79M | EV / Sales 2024 * | 1.01 x |
| Net Debt 2024 * | 52.53M 38.47M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.12 x |
| P/E ratio 2024 * |
-0.48
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Valeo Pharma Inc.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | Nov. 19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 18-07-24 |
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Marc Léger
BRD | Director/Board Member | 65 | 22-04-26 |
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-07-03
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.095
CAD
Average target price
0.5
CAD
Spread / Average Target
+426.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.25% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.25% | 233B | |
| +5.34% | 201B | |
| -10.22% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- VPH Stock
- VPH Stock
